instance, Foundation Medicine, Inc. and Pfizer, Inc. entered into a partnership for development,
regulatory support, and commercialization of companion diagnostics (CDx) in January 2018.
Moreover, Qiagen, Inc., and Freenome partnered in June 2018, to accelerate the development
and commercialization of Next-Generation Sequencing (NGS) tests to enable precision medicine
in cancer treatment.
Pierre Fabre and Roche have been working on development of a robust prototype
immunohistochemistry assay as a future companion diagnostic test for W0101 (the drug
candidate which they are developing together) and extended this collaboration in May 2018.
Abbott Laboratories, Inc. collaborated with Celgene Corporation, and Agios Pharmaceuticals, to
develop diagnostic tests on Abbott’s m2000 RealTime system that identifies certain genomic
mutations associated with acute myeloid leukemia (AML) in 2016. These factors are expected to
support global theranostics market growth over the forecast period.
Global Theranostics Market Regional Insights:-
North America is expected to witness significant growth in the global theranostics market over
the forecast period. Presence of leading manufacturers, collaborations, robust research, and
development activities, and increasing adoption of companion diagnostics is expected to support
global theranostics market growth over the forecast period. Biocartis Group NV and Amgen, Inc.
partnered to develop companion diagnostic test for Amgen's drug Vectibix (panitumumab) in
2017. For instance, Genome Canada launched a national initiative for clinical implementation of
precision health in June 2018, which would ultimately impact global theranostics market
growth over the forecast period.
Asia Pacific theranostics market is expected to witness significant growth over the forecast
period, owing to collaborations in the region by global organizations and increasing awareness
regarding companion diagnostics. For instance, Qiagen collaborated with Japan based clinical
lab testing company, SRL, Inc. for introduction of new companion diagnostics with new drug
approvals in August 2018.
Key players of Global Theranostics Market:-
Key players operating in the global theranostics market include Thermo Fisher Scientific, Inc.,
Beckman Coulter, Inc., Focus Diagnostics, AmeriPath, Inc., Illumina, Inc., F.Hoffmann LA-Roche
Ltd., Qiagen NV, Myriad Genetics, Inc., Agilent Technologies, Abbott Laboratories, Foundation
Medicine, Inc., and Oxford Cancer Biomarkers, Ltd.